Geode Capital Management’s Biofrontera BFRI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$88.4K Buy
109,300
+43,623
+66% +$37.5K ﹤0.01% 4165
2025
Q4
$37.4K Buy
65,677
+23,074
+54% +$20.8K ﹤0.01% 4286
2025
Q3
$42K Buy
42,603
+2,197
+5% +$1.99K ﹤0.01% 4326
2025
Q2
$28.8K Buy
40,406
+262
+0.7% +$183 ﹤0.01% 4320
2025
Q1
$32.1K Buy
40,144
+20,840
+108% +$21.4K ﹤0.01% 4272
2024
Q4
$21K Buy
19,304
+2,202
+13% +$2.08K ﹤0.01% 4379
2024
Q3
$22.8K Sell
17,102
-440
-3% -$504 ﹤0.01% 4382
2024
Q2
$15.8K Buy
+17,542
New +$24.2K ﹤0.01% 4490
2023
Q3
Sell
-4,064
Closed -$42.3K 4767
2023
Q2
$42.3K Sell
4,064
-91
-2% -$966 ﹤0.01% 4538
2023
Q1
$50.7K Hold
4,155
﹤0.01% 4518
2022
Q4
$76K Buy
4,155
+454
+12% +$9.27K ﹤0.01% 4486
2022
Q3
$77K Hold
3,701
﹤0.01% 4665
2022
Q2
$137K Buy
3,701
+506
+16% +$30.7K ﹤0.01% 4447
2022
Q1
$212K Buy
3,195
+1,981
+163% +$144K ﹤0.01% 4350
2021
Q4
$182K Buy
+1,214
New +$133K ﹤0.01% 4518

Other funds holding BFRI

Geode Capital Management's BFRI Position: Q1 2026 in Review

Geode Capital Management increased its Biofrontera (BFRI) stake by 66% in Q1 2026, buying an estimated $37.5K and bringing the position to 109,300 shares worth $88.4K. The position accounts for ﹤0.01% of the portfolio, ranked #4165.

Geode Capital Management first reported a position in BFRI in Q4 2021 and has held it in 15 quarters since. The position peaked at $212K in Q1 2022. 12 funds tracked by Wall St. Rank hold BFRI as of Q1 2026.

  • Geode Capital Management held 109,300 shares of Biofrontera worth $88.4K as of Q1 2026.
  • Geode Capital Management bought 43,623 Biofrontera shares in Q1 2026, an estimated $37.5K.
  • Biofrontera made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #4165 holding.
  • Geode Capital Management first reported a position in Biofrontera in Q4 2021 and has held it in 15 quarters since.
  • Geode Capital Management's Biofrontera position peaked at $212K in Q1 2022.
  • 12 funds tracked by Wall St. Rank held Biofrontera as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.